Overview

Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2007-02-05
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for intermediate-grade or immunoblastic non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have intermediate-grade or immunoblastic non-Hodgkin's lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Bleomycin
Cisplatin
Cyclophosphamide
Cytarabine
Doxorubicin
Etoposide
Etoposide phosphate
Idarubicin
Ifosfamide
Isophosphamide mustard
Liposomal doxorubicin
Mesna
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Mitoxantrone
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Prednisone
Vincristine